This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine

This study is currently recruiting participants.
See Contacts and Locations
Verified December 2016 by Butantan Institute
Sponsor:
Information provided by (Responsible Party):
Butantan Institute
ClinicalTrials.gov Identifier:
NCT02406729
First received: March 30, 2015
Last updated: December 19, 2016
Last verified: December 2016
  Purpose

This is a randomized, multicenter, double-blind, placebo-controlled Phase III study that will evaluate efficacy and safety of a live attenuated, tetravalent, lyophilized dengue vaccine produced by Butantan Institute.

The study will be carried out in multiple sites in Brazil. The study will be community-based in select urban areas where there's dengue transmission.

Study's intervention will be a single dose of the tetravalent dengue vaccine or placebo in a ratio 2:1. For efficacy analysis will be considered all dengue cases occurring after 28 days post-vaccination in the entire population of 16944 participants.

For safety analysis participants will be divided in three age groups: 18 to 59 ys, 7-17 ys and 2 to 6 ys. In each of these age groups there will be a minimum of 4992 participants. The age groups of 18 to 59 ys and 7 to 17 ys will start first. Once safety data for the first 21 days after vaccination is analysed for 450 participants in 7-to17-ys age group, the following group, of 2 to 6 ys, will start.

The study's hypothesis is that the vaccine under investigation and produced by Butantan Institute is safe and provides protection against dengue symptomatic disease of 80% or more with a lower bound of the 95% confidence interval of 25%. This way, the expected number of dengue cases virologically confirmed is 24 or more which will provide a response in terms of vaccine efficacy.

All participants will be followed up for five years to verify dengue incidence, regardless severity.


Condition Intervention Phase
Dengue Biological: Dengue 1,2,3,4 (attenuated) vaccine Other: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Phase III Trial to Evaluate Efficacy and Safety of a Dengue 1,2,3,4 (Attenuated) Vaccine

Resource links provided by NLM:


Further study details as provided by Butantan Institute:

Primary Outcome Measures:
  • Efficacy (incidence density of symptomatic dengue cases, virologically confirmed) [ Time Frame: at 52 weeks post vaccination, all cases after 28 days post-vaccination ]
    • The primary efficacy outcome is incidence density of symptomatic dengue cases, virologically confirmed, after 28 days post-vaccination. Virological confirmation might be done by viral isolation, RT-PCR and/or detection of NS1.

  • Safety (adverse reactions) [ Time Frame: in the first 21 days post-vaccination ]
    • The primary safety outcome is the frequency of local and systemic adverse reactions, solicited and non-solicited in the three age groups, within the first 21 days post-vaccination. Adverse reactions are defined as adverse events that have a reasonable causal relationship with vaccination.


Estimated Enrollment: 16944
Study Start Date: February 2016
Estimated Study Completion Date: November 2022
Estimated Primary Completion Date: May 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dengue 1,2,3,4 (attenuated) vaccine
Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
Biological: Dengue 1,2,3,4 (attenuated) vaccine
Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
Other Names:
  • Butantan DV
  • TetraVax-DV-TV003
Placebo Comparator: Placebo
Placebo Single dose, SC
Other: Placebo
Route:subcutaneous

  Eligibility

Ages Eligible for Study:   24 Months to 59 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Children who have completed 24 months of age, adolescents and adults who have not completed 60 years of age;
  2. Agree with periodic contacts, either/or by phone, electronic means, and home visits.
  3. Show voluntary intention to participate in the study, documented by the participant's or participant's legal representative's signature of the informed consent form.

Exclusion Criteria:

  1. For women: Pregnancy (confirmed by positive beta-hCG test) or breastfeeding;
  2. Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as per clinical history and/or physical examination;
  3. Compromised immune system diseases including: decompensated diabetes mellitus, cancer (except basal cell carcinoma), congenital or acquired immune deficiencies and not controlled autoimmune, as per clinical history and/or physical examination;
  4. Behavioral, cognitive or psychiatric disease that in the opinion of the principal investigator or his representative physician, affects the participant ability to understand and cooperate with all study protocol requirements;
  5. Abusive usage of alcohol or drugs in the past 12 months that has caused medical, professional or family problems, indicated by clinical history;
  6. History of severe allergic reactions or anaphylaxis to the vaccine or to components of the vaccine in study;
  7. History of asplenia;
  8. Use of any investigational product within 28 days before or after receiving this study vaccination;
  9. Has participated in another clinical trial six months prior to inclusion in the study or planning to participate in another clinical trial within 2 years following inclusion;
  10. Use of immunosuppressant drugs such as: antineoplastic chemotherapy, radiation therapy, immunosuppressants to induce tolerance to transplants, and corticosteroids use (except topical or nasal). For this protocol will be considered for exclusion use of corticosteroids 3 months prior to the inclusion in the study and 6 months prior to the inclusion for the other therapies mentioned, and planned use of any immunosuppressant therapy within 2 years following inclusion in the study. It will be considered immunosuppressive dose of corticosteroids the equivalent to a dose ≥20 mg of prednisone per day for adults and the equivalent of prednisone at 2 mg/kg/day for children for over 7 days;
  11. Have received blood products in the past three months, including transfusions or immunoglobulin, or scheduled administration of blood products or immunoglobulin for the following 2 years after vaccination;
  12. Fever or suspected fever within 72 hours prior to vaccination or axillary temperature greater than 37,8°C on the day of vaccination (inclusion might be postponed until participant has completed 72 hours of no fever);
  13. Have received live virus vaccine within 28 days or killed virus vaccine in the last 14 days prior to vaccination, or have a scheduled immunization during the first 28 days after receiving the investigational product;
  14. Any other condition that might put in risk the safety/rights of a potential participant or hurdle his/her compliance with this protocol in investigator's opinion or his representative physician.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02406729

Contacts
Contact: Alexander R Precioso, MD, PhD +55(11)26279372 alexander.precioso@butantan.gov.br
Contact: Ricardo Palacios, MD, PhD +55(11)26279372 ricardo.palacios@butantan.gov.br

Locations
Brazil
Fundação de Medicina Tropical Doutor Heitor Vieira Dourado Recruiting
Manaus, Amazonas, Brazil, 69040-000
Contact: Marcus Lacerda, MD, PhD         
Principal Investigator: Marcus Lacerda, MD, PhD         
Universidade Federal do Ceará Recruiting
Fortaleza, CE, Brazil, 60430-160
Contact: Ivo Castelo Branco Coelho, MD, PhD         
Principal Investigator: Ivo Castelo Branco Coelho, MD, PhD         
Universidade de Brasília Recruiting
Brasilia, DF, Brazil, 71691-082
Contact: Gustavo Adolfo Sierra Romero, Sierra Romero         
Principal Investigator: Gustavo Adolfo Sierra Romero, MD, PhD         
Universidade Federal de Minas Gerais Recruiting
Belo Horizonte, MG, Brazil, 30750-140
Contact: Mauro M Teixeira, MD, PhD         
Contact: Helton Santiago, MD, PhD         
Principal Investigator: Mauro M Teixeira, MD, PhD         
Principal Investigator: Helton Santiago, MD, PhD         
Universidade Federal de Mato Grosso do Sul Recruiting
Campo Grande, MS, Brazil, 79070-900
Contact: Erivaldo Elias Jr., MD         
Principal Investigator: Erivaldo Elias Jr., MD         
Hospital Universitário Júlio Müller da Universidade Federal de Mato Grosso Recruiting
Cuiabá, MT, Brazil, 78048-610
Contact: Cor J Fontes, MD, PhD         
Principal Investigator: Cor J Fontes, MD, PhD         
Centro de Pesquisas Aggeu Magalhães - Fiocruz Pernambuco Recruiting
Recife, Pernambuco, Brazil, 50740-465
Contact: Ernesto TA Marques, MD, PhD         
Contact: Rafael Dhalia, PhD         
Principal Investigator: Ernesto TA Marques, MD, PhD         
Principal Investigator: Rafael Dhalia, PhD         
Universidade Federal de Roraima - UFRR Recruiting
Boa Vista, Roraima, Brazil, 69304-000
Contact: Allex J da Fonseca, MD, PhD         
Principal Investigator: Allex J da Fonseca, MD, PhD         
Centro de Pesquisas em Medicina Tropical de Rondônia (CEPEM) Recruiting
Porto Velho, RO, Brazil, 78918-791
Contact: Dhelio B Pereira, MD, PhD         
Principal Investigator: Dhelio B Pereira, MD, PhD         
Hospital São Lucas da Pontificia Universidade Catolica do Rio Grande do Sul Recruiting
Porto Alegre, RS, Brazil, 90619-900
Contact: Fabiano Ramos, MD         
Contact: Cristina C Bonorino, PhD         
Principal Investigator: Fabiano Ramos, MD         
Principal Investigator: Cristina C Bonorino, PhD         
Universidade Federal de Sergipe Recruiting
Laranjeiras, SE, Brazil, 49170-000
Contact: Ricardo Q Gurgel, MD, PhD         
Principal Investigator: Ricardo Q Gurgel, MD, PhD         
Santa Casa de Misericórdia de São Paulo - CSEBF Recruiting
São Paulo, SP, Brazil, 01133-020
Contact: José Cássio de Moraes, MD, PhD         
Principal Investigator: José Cássio de Moraes, MD, PhD         
Sub-Investigator: Hilda Salinas, MD         
Faculdade de Medicina de São José do Rio Preto - FAMERP Recruiting
São José de Rio Preto, São Paulo, Brazil, 15090-000
Contact: Maurício L Nogueira, MD, PhD         
Principal Investigator: Maurício L Nogueira, MD, PhD         
HCFMUSP Recruiting
São Paulo, Brazil, 05403-000
Contact: Esper G Kallas, MD, PhD         
Principal Investigator: Esper G Kallas         
Sponsors and Collaborators
Butantan Institute
Investigators
Study Director: Alexander R Precioso, MD, PhD Butantan Institute
Study Chair: Ricardo Palacios, MD, PHD Butantan Institute
Principal Investigator: Esper G Kallas, MD, PhD School of Medicine, University of São Paulo
  More Information

Publications:
Responsible Party: Butantan Institute
ClinicalTrials.gov Identifier: NCT02406729     History of Changes
Other Study ID Numbers: DEN-03-IB
U1111-1168-8679 ( Registry Identifier: UTN )
Study First Received: March 30, 2015
Last Updated: December 19, 2016

Additional relevant MeSH terms:
Dengue
Arbovirus Infections
Virus Diseases
Flavivirus Infections
Flaviviridae Infections
RNA Virus Infections
Hemorrhagic Fevers, Viral
Vaccines
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 17, 2017